ChronVac-C Reducing HCV Viral Load Up to 99%
Although it is early in the process and only involves a few subjects, interim trial results for ChronVac-C show extremely high percentages of Hepatitis C viral load reduction.
Continue reading »Research & Treatment News
Share
Follow Us
Hepatitis C Patients: Drink More Coffee for a Healthier Liver
Demonstrating a hepatoprotective effect against Hepatitis C, the world's number one morning beverage lands a victory in the debate over its healthfulness.
Continue reading »Who Will Respond to Hepatitis C Treatment
The relatively new field of proteomics may be able to predict who will respond to Hepatitis C therapy - before treatment even begins.
Continue reading »Antivirals Combined Without Interferon: New Trial
Three companies unite to begin an innovative Hepatitis C trial, where two oral antiviral drugs will be combined in the absence of interferon.
Continue reading »HCV May Be Able to Be Cleared from Both Blood and Liver
Viral clearance doubled in a Hepatitis C Phase II trial during standard therapy when coupled with GlobeImmune's GI-5005. Because Hepatitis C must be eradicated not just from the blood, but also the liver, GI-5005's ability to speed the clearance rate of infected cells from the liver shows great therapeutic promise.
Continue reading »How to Afford HCV Treatment
Some Hepatitis C patients may choose not to attempt antiviral therapy for many different reasons. However, with the resources available today, financial reasons can be excluded from deciding whether or not to receive treatment.
Continue reading »FDA Approves Roche's Hep C Viral Load Measurements Test
Roche's COBAS® AmpliPrep / COBAS® TaqMan® Test brings improved ease, speed and accuracy to Hepatitis C viral load measurements, and was just approved by the FDA.
Continue reading »Vertex Treatment May Also Help Non-Responders
Here's some news to be announced at next week's meeting of the American Association for the Study of Liver Diseases. Vertex Pharmaceuticals will release mid-stage study results indicating the effectiveness of its experimental drug, telaprevir. This recent study, known as Prove 3, focused on 453 patients who had failed previous treatment with pegylated-interferon and ribavirin. The exciting news is that 52 percent of them saw the virus fall to undetectable levels for a 12-week period following treatment. In this article you'll learn how telaprevir might shorten treatment time by half, whether reducing dosage frequency could affect its safety, and how sustained viral response rate is determined.
Continue reading »HCV Treatment for U.S. Prisoners
Despite the prevalence of Hepatitis C infection in the U.S. prison population, some inmates are denied treatment due to the medications' high cost. However, a UCLA study insists that treating all infected U.S. prisoners with the standard therapy would actually be cost-effective.
Continue reading »Safer Than Liver Biopsy: A Simple Breath Test for HCV
A specially designed breath test has been found to be a safe and accurate alternative to liver biopsy for determining the degree of inflammation and fibrosis in patients with chronic Hepatitis C infection and normal ALT, according to researchers from Jerusalem.
Continue reading »
